Research programme: retinoid-related orphan receptor antagonists - Bristol-Myers Squibb/ExelixisAlternative Names: RORγ antagonists - Bristol-Myers Squibb/Exelixis; RORγ-t antagonists - Bristol-Myers Squibb/Exelixis
Latest Information Update: 09 Sep 2016
At a glance
- Originator Bristol-Myers Squibb; Exelixis
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 13 Oct 2010 Early research in Inflammation in USA (unspecified route)